U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Meta Expands AI Training With Employee Activity Tracking Tools 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SOUTH SAN FRANCISCO, Calif., March 01, 2016 -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold’s Chief Executive Officer, will present a company overview at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016, at 9:20 a.m. Eastern Time.
A live webcast of the presentation will be available under "Webcasts" in the Investors section of www.thresholdpharm.com. A replay of the presentation will be archived on the site for 30 days.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors, as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we have a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its drug candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to: Threshold’s need for and the availability of resources to develop its drug candidates and to support Threshold's operations including the expense required to conduct clinical trials and analyze data; issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on November 2, 2015 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.
Contact Mark Hopkins, Ph.D., J.D. Vice President of Intellectual Property and Assistant General Counsel Phone: 650-474-8213 E-mail: [email protected]
